Proceedings of the Texas A&M Medical Student Grand Rounds

The Role of Micro-RNAs in Glioblastoma Biology

May 31, 2022 Kishore Balasubramanian

Kishore Balasubramanian

Introduction. Glioblastoma multiforme (GBM) is one of the most common and fatal primary brain tumors. It is characterized by aggressive proliferation and motility and is highly resistant to conventional radiation and chemotherapy. Research into the dynamic interaction between microenvironment and the biological mechanisms specific to GBM cancer cells is rich with potential in identifying new therapeutic targets and improving treatment. One such area is identifying and targeting micro-RNAs (miRNA) that drive the different hallmarks of cancer. Methods. Four different miRNAs were studied in the context of GBM biology. miR-138, miR-137, miR-376a, and miR-451 to assess cell proliferation, chemoresistance, angiogenesis, and cell migration respectively. Lentivirus transduction was used to ectopically induce miRNA expression, luciferase assay was used to confirm miRNA expression, Transwell/wound healing assay was used to assess cell migration, and CCK8/MTT Assay was used to measure cell viability. PCR and Western blotting were used to determine specific biological mechanisms. Results. miR-376a was downregulated in patient cell lines. Induced expression of miR-376a directly targets and inhibits SIRT1 in glioma cells which in turn decreased YAP1 and VEGF signaling. Overall, this led to suppression of glioma cell proliferation, migration and angiogenesis.1 miR-451 expression is based on glucose concentration. In glucose + conditions, the cells showed relatively high miR-451 expression, promoting cell growth. In glucose – conditions, miR-451 levels decreased, slowing proliferation but enhancing migration. These effects were mediated through the LKB1/AMPK pathway.2 Genomic analysis of patient cell lines showed that cell proliferation was mediated by the downregulation of miR-138. However, transient overexpression of miR-138 in GBM cells inhibited cell proliferation. Molecular studies showed that miR-138 downregulated CD44 expression which led to expression of p27 and cell cycle arrest.3 Finally, chemoresistance was mediated by miR-137. miR-137 was downregulated in GBM samples as compared with normal brain tissues. Induced overexpression of miR-137 inhibited cell invasion and enhanced cell chemosensitivity to temozolomide (TMZ). This effect was mediated through the downregulation of the LRP6 receptor.4 Conclusion. Taken together, these results demonstrate the potential in targeting micro RNAs in glioblastoma management and treatment. With the advent of next generation sequencing technologies, micro-RNA based therapies can allow for personalized and effective diagnostics and therapeutics and avoid the systemic toxic effects seen with conventional treatment.

  1. Deng, Yong-Wen et al. “miR-376a inhibits glioma proliferation and angiogenesis by regulating YAP1/VEGF signalling via targeting of SIRT1.” Translational oncology vol. 15,1 (2022): 101270. doi:10.1016/j.tranon.2021.101270
  2. Godlewski J, Nowicki MO, Bronisz A, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620-632. doi:10.1016/j.molcel.2010.02.018
  3. Yeh, Margaret et al. “MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44.” Scientific reports vol. 11,1 9219. 28 Apr. 2021, doi:10.1038/s41598-021-88615-8
  4. Li DM, Chen QD, Wei GN, et al. Hypoxia-Induced miR-137 Inhibition Increased Glioblastoma Multiforme Growth and Chemoresistance Through LRP6. Front Oncol. 2021;10:611699. Published 2021 Feb 25. doi:10.3389/fonc.2020.611699

 

 

Cancer Featured Abstracts
Previous Post

CRISPR Base Editors as a Therapeutic Agent to Reduce Pathogenesis of Mutant SOD1 Gene In Amyotrophic Lateral Sclerosis (ALS)

Next Post

The Use of Kartogenin to Restore the Native Enthesis of Rotator Cuff Injuries

Scientific Editors

Steve A. Maxwell

Executive Editor
Tel: 979-436-0804
smaxwell@medicine.tamhsc.edu

Robin Fuchs-Young

Deputy Editor
Tel: 979-845-5109
fuchs-young@medicine.tamhsc.edu
Administrative Editor

Janis Chmiel

Tel: 979-436-0856
chmiel@medicine.tamhsc.edu
Editorial Office
Tel.: 979-845-2726
Fax: 979-847-9481
chmiel@medicine.tamhsc.edu
Archives
  • July 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • May 2025
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • November 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • August 2022
  • June 2022
  • May 2022
  • August 2021
  • July 2021
  • April 2021
  • October 2020
  • August 2020
  • July 2020
  • August 2019
  • July 2019
  • February 2019
  • July 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • January 2017
Proudly powered by WordPress | Theme: Fmi by Forrss.